TABLE 3.
Patient outcomesa
| Unweighted cohort | Propensity-score-weighted cohort | |||||
|---|---|---|---|---|---|---|
| Albumin ≤ 2.5 g/dL (N = 34) |
Albumin >2.5 g/dL (N = 103) |
P value | Albumin ≤2.5 g/dL (N = 34) |
Albumin >2.5 g/dL (N = 103) |
P value | |
| Clinical success | 26 (76.5%) | 95 (92.2%) | 0.013 | 77.8% | 91.2% | 0.038 |
| Clinical cure | 26 (76.5%) | 96 (93.2%) | 0.007 | 77.8% | 92.0% | 0.024 |
| Microbiologic cure | 29 (85.3%) | 97 (94.2%) | 0.10 | 81.9% | 93.2% | 0.055 |
| Hospital length of stay (days), median (IQR) |
14 (8, 28) | 9 (6, 16) | 0.009 | 10 (7, 27) | 9 (6, 15) | 0.21 |
| ICU Length of stay (days), median (IQR) |
3.5 (2.1, 14.2) | 2.5 (1.5, 5.7) | 0.088 | 3.5 (2.0, 13.7) | 2.4 (1.3, 5.4) | 0.092 |
| Death during hospitalization | 5 (14.7%) | 0 (0.0%) | <0.001 | 13.5% | 0.0% | <0.001 |
| Death within 30 days | 5 (14.7%) | 0 (0.0%) | <0.001 | 13.7% | 0.0% | <0.001 |
| Death within 60 days | 8 (23.5%) | 1 (1.0%) | <0.001 | 22.6% | 0.8% | <0.001 |
| Readmission within 30 days | 8 (23.5%) | 12 (11.7%) | 0.089 | 31.6% | 12.0% | 0.008 |
| Adverse effects | 0.72 | 0.60 | ||||
| Neutropenia | 0 (0.0%) | 2 (1.9%) | 0.0% | 3.0% | ||
| Rash or other suspected IgE-mediated allergic reactionb | 1 (2.9%) | 3 (2.9%) | 2.7% | 2.6% | ||
| None identified | 33 (97.1%) | 98 (95.1%) | 97.3% | 94.4% | ||
a
ICU, intensive care unit; g/dL, grams per deciliter; IQR, interquartile range.
b
Suspected IgE-mediated reactions included hives, urticaria, angioedema, or anaphylaxis.